title: The effect of etodolac on experimental temporomandibular joint osteoarthritis in dogs.
abstract: OBJECTIVE
  The purpose of this study was to test the effect of etodolac on a dog model of osteoarthritic temporomandibular joints (TMJ).
  
  
  METHODS
  Ten adult beagle dogs underwent surgery to induce osteoarthritis in the right TMJ, and were then randomly divided into two groups each of 5 dogs. From 2 to 6 weeks after surgery, the dogs in group 1 (control group) were given an empty gelatin capsule daily, and the dogs in group 2 (study group) were given 15 mg/kg of etodolac daily. All joints were examined radiologically and histologically 8 weeks postoperatively.
  
  
  RESULTS
  In group 1, the operated right joints showed severe osteoarthritic changes in the condyle and severe morphological differences in comparison with the unoperated (left joint). Group 2 showed fewer morphological differences between the unoperated control (left) and the operated (right) TMJ. Osteoarthritic changes in the TMJ were significantly less severe in group 2 (etodolac) than in group 1.
  
  
  CONCLUSIONS
  Oral administration of etodolac at a dose of 15 mg/kg minimized the continuation of experimentally induced osteoarthritic changes in the canine TMJ, when compared with the placebo. Thus, etodolac may play a role in preventing progression of human TMJ osteoarthritis.
authors.affiliation: Second Division of Oral and Maxillofacial Surgery, Department of Diagnosis & Therapeutic Science, Meikai University School of Dentistry, Sakado, Saitama, Japan. hezlu@dent.meikai.ac.jp
authors.forename: Hizuru
authors.initials: H
authors.lastname: Miyamoto
authors.forename: Hiroomi
authors.initials: H
authors.lastname: Onuma
authors.forename: Hisao
authors.initials: H
authors.lastname: Shigematsu
authors.forename: Seiji
authors.initials: S
authors.lastname: Suzuki
authors.forename: Hideaki
authors.initials: H
authors.lastname: Sakashita
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D016723:Bone Remodeling / Q000187:drug effects; D002358:Cartilage, Articular / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology; D004195:Disease Models, Animal; D004285:Dogs; D017308:Etodolac / Q000008:administration & dosage / Q000627:therapeutic use*; D005355:Fibrosis; D008335:Mandibular Condyle / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology; D010003:Osteoarthritis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D054850:Osteophyte / Q000000981:diagnostic imaging / Q000473:pathology; D010026:Osteosclerosis / Q000000981:diagnostic imaging / Q000473:pathology; D010919:Placebos; D011859:Radiography; D011897:Random Allocation; D013701:Temporal Bone / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology; D013705:Temporomandibular Joint Disorders / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010919:Placebos; D017308:Etodolac